Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 10-0906-CE | Other Identifier | Research Ethics Board |
Not provided
Not provided
Not provided
Poor patient accrual
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a study to determine the prevalence and severity of alopecia (hair loss) experienced by postmenopausal breast cancer patients receiving endocrine therapy including Tamoxifen, Letrozole (Femara), Exemestane (Aromasin), or Anastrozole (Arimidex).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Postmenopausal Women on Endocrine Therapy | Postmenopausal women with Breast Cancer that undergo Endocrine Therapy. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Severity of Alopecia Tool (SALT) | The proportion of postmenopausal breast cancer patients on endocrine therapy who experience grade S1 to S5 alopecia as defined by the Severity of Alopecia Tool (SALT). | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of Tamoxifen, AI or Tamoxifen plus AI | Comparison of the proportion of postmenopausal breast cancer patients treated with Tamoxifen monotherapy, AI monotherapy, or a switch from Tamoxifen to AI who experience alopecia. | 1 year |
| Severity of Alopecia Tool (SALT) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients that attend Medical Oncology Breast Clinics at Princess Margaret Hospital.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lindsay Carlsson | University Health Network-Princess Margaret Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Princess Margaret Hospital | Toronto | Ontario | M5G 3M9 | Canada |
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
To identify the severity, or grade, of hair loss experienced by our target population. The severity of alopecia will be represented as a percentage, again in accordance with the SALT. |
| 1 year |
| D017437 |
| Skin and Connective Tissue Diseases |